Heterogeneous nuclear ribonucleoprotein K is a potential target for enhancing the chemosensitivity of nasopharyngeal carcinoma DOI Creative Commons
Ming Yang,

Zhaoyang Ke,

Daji Wang

et al.

Open Life Sciences, Journal Year: 2024, Volume and Issue: 19(1)

Published: Jan. 1, 2024

Abstract The resistance of tumor cells to chemotherapy drugs is a critical determinant in the recurrence and metastasis nasopharyngeal carcinoma (NPC). Therefore, it crucial identify effective biotargets that can enhance sensitivity NPC drugs. Heterogeneous nuclear ribonucleoprotein K (hnRNPK) plays central role regulating across various types. However, its specific function remains unclear. This study reveals hnRNPK overexpressed tissues while weakly expressed normal tissues. expression level negatively associated with patient survival. Importantly, key inducer NPC, as evidenced by significant increase cell cisplatin following knockdown. Mechanistically, induces suppressing activation Akt/caspase 3 pathway. In tumor-bearing mice, knockdown enhances efficacy chemotherapy. Consequently, this work identifies potential target for enhancing

Language: Английский

Mitochondrial signaling pathways and their role in cancer drug resistance DOI
Ashwani Sharma, Tarun Virmani, Girish Kumar

et al.

Cellular Signalling, Journal Year: 2024, Volume and Issue: 122, P. 111329 - 111329

Published: Aug. 5, 2024

Language: Английский

Citations

9

N‐acetylcysteine for the Prevention of Cisplatin‐Induced Hearing Loss: A Systematic Review and Meta‐analysis DOI

J Plane,

Thamiris Dias Delfino Cabral, Renata M. Knoll

et al.

Otolaryngology, Journal Year: 2025, Volume and Issue: unknown

Published: May 5, 2025

Abstract Objective Cisplatin is an effective antineoplastic drug used worldwide in the treatment of various malignancies. However, it associated with side effects, including cisplatin‐induced hearing loss (CIHL). N‐acetylcysteine (NAC) has been suggested as a promising to prevent or reduce cisplatin‐derived ototoxicity. To evaluate evidence supporting efficacy NAC preventing CIHL, we conducted systematic review and meta‐analysis literature. Data Sources A search was on PubMed, Embase, Web Science, Clinicaltrials.gov , Cochrane Library. Review Methods Articles reporting administration systemic transtympanic injection for CIHL prevention were considered. The outcomes interest included presence events changes thresholds at 0.5 through 12 kHz following cisplatin treatment. Results total 7 studies involving 217 patients met inclusion criteria. Of these patients, 175 received NAC, remaining NAC. No significant differences found between use either compared placebo (risk ratio [RR] 0.80; 95% confidence interval [CI] 0.54‐1.19; P = .28, RR 0.89; CI 0.51‐1.54; .67, respectively). 8 groups. Qualitative analyses tendency otoprotection ultra‐high frequencies (10 kHz). Conclusion Our findings suggest that, regardless route, current published does not show that standard clinical audiogram range. Further larger samples are needed confirm our findings. Level Evidence I.

Language: Английский

Citations

0

Evaluating N-acetylcysteine for mitigating cisplatin-induced oxidative stress and ionocyte damage in a zebrafish model DOI

Szu-Jung Chen,

Ciao-Ling Wu,

Li‐Yih Lin

et al.

Toxicology and Applied Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 117401 - 117401

Published: May 1, 2025

Language: Английский

Citations

0

Leonurine protects against cisplatin-induced ototoxicity through its anti-oxidation and anti-apoptosis properties DOI
Zhen Zeng, Lei Han,

D. P. Dong

et al.

Toxicology Letters, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Language: Английский

Citations

0

Neuroprotective mechanisms and ameliorative activities of quercetin in cisplatin-induced cerebellum neurotoxicity in rat models DOI Creative Commons
Sunday Aderemi Adelakun, Babatunde Ogunlade,

Julius Akomaye Aniah

et al.

Brain Disorders, Journal Year: 2024, Volume and Issue: unknown, P. 100166 - 100166

Published: Oct. 1, 2024

Language: Английский

Citations

1

Renogrit selectively protects against cisplatin-induced injury in human renal tubular cells and in Caenorhabditis elegans by harmonizing apoptosis and mitophagy DOI Creative Commons
Acharya Balkrishna, Vivek Gohel,

Nishit Pathak

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Aug. 21, 2024

Cisplatin-induced nephrotoxicity restricts its clinical use against solid tumors. The present study elucidated the pharmacological effects of Renogrit, a plant-derived prescription medicine, using cisplatin-induced human renal proximal tubular (HK-2) cells and Caenorhabditis elegans. Quantification phytochemicals in Renogrit was performed on HPTLC UHPLC platforms. assessed vitro HK-2 post-exposure to clinically relevant concentration cisplatin. It observed that renoprotective properties injury stem from ability regulate markers (KIM-1, NAG levels; NGAL mRNA expression), redox imbalance (ROS generation; GST levels), mitochondrial dysfunction (mitochondrial membrane potential; SKN-1, HSP-60 expression). also found modulate apoptosis (EGL-1 expression; protein levels p-ERK, p-JNK, p-p38, c-PARP1), necroptosis (intracellular calcium accumulation; RIPK1, RIPK3, MLKL mitophagy (lysosome population; expression PINK1, PDR1; p-PINK1, LC3B), inflammation (IL-1β activity; LXR-α). More importantly, treatment did not hamper normal anti-proliferative cisplatin as cytotoxicity analysis MCF-7, A549, SiHa, T24 cancer cells. Taken together, could be potential candidate mitigate without compromising anti-neoplastic

Language: Английский

Citations

0

Importance of Selected Antioxidants in Carcinogenesis and Cancer Therapy DOI
Natalia Kurhaluk, Piotr Kamiński,

Halina Tkaczenko

et al.

Interdisciplinary cancer research, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Language: Английский

Citations

0

Heterogeneous nuclear ribonucleoprotein K is a potential target for enhancing the chemosensitivity of nasopharyngeal carcinoma DOI Creative Commons
Ming Yang,

Zhaoyang Ke,

Daji Wang

et al.

Open Life Sciences, Journal Year: 2024, Volume and Issue: 19(1)

Published: Jan. 1, 2024

Abstract The resistance of tumor cells to chemotherapy drugs is a critical determinant in the recurrence and metastasis nasopharyngeal carcinoma (NPC). Therefore, it crucial identify effective biotargets that can enhance sensitivity NPC drugs. Heterogeneous nuclear ribonucleoprotein K (hnRNPK) plays central role regulating across various types. However, its specific function remains unclear. This study reveals hnRNPK overexpressed tissues while weakly expressed normal tissues. expression level negatively associated with patient survival. Importantly, key inducer NPC, as evidenced by significant increase cell cisplatin following knockdown. Mechanistically, induces suppressing activation Akt/caspase 3 pathway. In tumor-bearing mice, knockdown enhances efficacy chemotherapy. Consequently, this work identifies potential target for enhancing

Language: Английский

Citations

0